Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 87.14% ano a ano.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ .
Sobreavaliada
O PE mais recente da empresa é 7.42, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 53.21M ações, uma redução de 5.81% em relação ao trimestre anterior.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.99.